What is the current Insulin Glulisine Injection market size?

The current Insulin Glulisine Injection market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Insulin Glulisine Injection market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing diabetes prevalence.

What are the key drivers of the Insulin Glulisine Injection market?

Key drivers include rising demand for fast-acting insulins and growing awareness of diabetes management, shaping the future outlook.

What are the major challenges facing the Insulin Glulisine Injection market?

Challenges include high development costs and stringent regulatory requirements, impacting market growth and future opportunities.

Which regions are the leaders in the Insulin Glulisine Injection market?

North America and Europe are the leading regions, driven by high healthcare expenditure and advanced infrastructure, influencing the market size.

Who are the top companies in the Insulin Glulisine Injection market?

Top companies include Sanofi, Eli Lilly, and Novo Nordisk, which are investing in research and development to drive growth and expansion.

What are the future opportunities in the Insulin Glulisine Injection market?

Future opportunities include emerging markets and innovative drug delivery systems, offering potential for growth and increased market share.

How is technology impacting the Insulin Glulisine Injection market?

Technology is driving innovation in insulin delivery systems and biosimilars, transforming the market landscape and future outlook.

What is the current regulatory landscape for the Insulin Glulisine Injection market?

The regulatory landscape is characterized by strict approval processes and patent protections, shaping the market dynamics and growth prospects.

Insulin Glulisine Injection Growth Trends & Strategic Outlook 2033

Insulin Glulisine Injection by Application (Hospital, Clinic, Others), by Types (3ml, 10ml), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Insulin Glulisine Injection Market Overview

The Insulin Glulisine Injection market refers to the global marketplace for insulin glulisine, a rapid-acting insulin analog used to manage blood sugar levels in individuals with diabetes. As the Insulin Glulisine Injection market size is expected to witness significant growth, driven by the increasing prevalence of diabetes and the growing demand for rapid-acting insulin analogs, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is anticipated to be fueled by advancements in insulin delivery technologies, changing consumer behavior, and the rising awareness about diabetes management, with the current market size estimated to be around $2.5 billion.

Loading chart…

The Insulin Glulisine Injection market is expected to grow at a CAGR of around 7-8% during the forecast period, driven by macro drivers such as the increasing prevalence of diabetes, advancements in insulin delivery technologies, and the growing demand for rapid-acting insulin analogs. Key forces shaping the industry include technology shifts, such as the development of novel insulin delivery systems, regulations, such as those related to insulin pricing and accessibility, and consumer behavior, such as the growing awareness about diabetes management. The largest region for the Insulin Glulisine Injection market is expected to be North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by the increasing prevalence of diabetes and the growing demand for insulin glulisine in these regions.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.43 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Eli Lilly and Company; Novo Nordisk; Biocon; Gan & Lee Pharmaceuticals; Dongyangguang Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Insulin Glulisine Injection market is poised for significant growth, driven by increasing demand for effective diabetes management solutions. The Insulin Glulisine Injection market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Rising prevalence of diabetes and growing awareness about the importance of timely insulin administration are fueling the demand for Insulin Glulisine Injection, thereby driving the market growth.

Advancements in insulin delivery technologies, such as pens and pumps, are making Insulin Glulisine Injection more convenient and accessible, contributing to the market's expansion.

Restraints2 items

Stringent regulatory requirements and high development costs associated with Insulin Glulisine Injection are limiting the entry of new players, thus restraining the market growth.

Competition from alternative diabetes treatments, such as oral medications and glucagon-like peptide-1 receptor agonists, is also hindering the adoption of Insulin Glulisine Injection.

Opportunities2 items

Emerging economies with large diabetic populations present significant opportunities for the Insulin Glulisine Injection market, driven by increasing healthcare expenditure and improving access to diabetes care.

Growing focus on developing biosimilar insulins, including Insulin Glulisine Injection, is expected to reduce costs and increase affordability, further expanding the market.

Challenges2 items

Maintaining a stable and efficient supply chain is a significant challenge for the Insulin Glulisine Injection market, given the complexities of insulin production and the need for cold chain logistics.

Ensuring patient adherence to insulin therapy and addressing concerns around hypoglycemia and injection site reactions are critical challenges that must be addressed to optimize the benefits of Insulin Glulisine Injection.

Market Segmentation

Loading chart…

The Application segment of the Insulin Glulisine Injection market refers to the various uses of Insulin Glulisine Injection in treating different types of diabetes. This segment includes Type 1 diabetes and Type 2 diabetes. The Insulin Glulisine Injection segmentation is crucial in understanding the market size and growth potential. The application segment contributes significantly to the overall market size, with each subtype having a distinct market share. For instance, Type 1 diabetes accounts for a larger share due to the increasing prevalence of the condition worldwide.

The Types segment of the Insulin Glulisine Injection market is categorized into subtypes, including Rapid-acting insulin, Short-acting insulin, and Long-acting insulin. Each subtype has a unique characteristic and is used to treat different types of diabetes. The market taxonomy of Insulin Glulisine Injection is essential in understanding the competitive landscape and identifying opportunities for growth. The types segment is critical in determining the market size, with rapid-acting insulin being the most widely used due to its fast onset of action.

Insulin Glulisine Injection Segmentation Breakdown7 items

Application

Hospital

Clinic

Others

Types

3ml

10ml

Regional Insights

Loading chart…

The Insulin Glulisine Injection market growth is expected to vary across regions, with the largest share attributed to North America, accounting for approximately 35% of the global market. The Asia Pacific region is anticipated to be the fastest-growing, driven by increasing adoption of Insulin Glulisine Injection, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, increasing demographics of diabetic patients, mature ecosystem maturity, and high infrastructure development; for Europe, growing demand for insulin glulisine, supportive regulations, and a well-established healthcare system; for Asia Pacific, rising awareness of diabetes management, expanding healthcare access, and increasing government initiatives; for Latin America, improving economic conditions, growing middle-class population, and rising healthcare spending; and for Middle East & Africa, increasing prevalence of diabetes, growing investment in healthcare, and developing healthcare infrastructure.

The regional forecast indicates that the Insulin Glulisine Injection market will experience significant growth, driven by increasing demand for effective diabetes management solutions. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay competitive in the global Insulin Glulisine Injection market.

Competitive Landscape

The Insulin Glulisine Injection market is moderately consolidated, with a mix of global players and local companies competing for market share. The Insulin Glulisine Injection competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players such as Sanofi and Eli Lilly and Company have a significant presence, while local companies like Dongyangguang Pharmaceuticals also play a crucial role in shaping the market.

Companies in the Insulin Glulisine Injection market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on competitive differentiation through technology, service model, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

Sanofi: regional expansion

Eli Lilly and Company: innovation pipeline

Novo Nordisk: premium pricing

Biocon: OEM tie-ups

Gan & Lee Pharmaceuticals: local manufacturing

Dongyangguang Pharmaceuticals: vertical integration

Key Insulin Glulisine Injection Companies6 items

Sanofi

Eli Lilly and Company

Novo Nordisk

Biocon

Gan & Lee Pharmaceuticals

Dongyangguang Pharmaceuticals

Market Ecosystem

The Insulin Glulisine Injection ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream activities. This ecosystem is characterized by the interplay between technology providers, suppliers, integrators, channels, and end users, all of which contribute to the creation and capture of value. The Insulin Glulisine Injection ecosystem is shaped by the interactions among these stakeholders, influencing how value is created, delivered, and captured.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing Insulin Glulisine Injection

Technology providers — developing formulation and delivery technologies

Distributors / channel partners — enabling product distribution

Service providers / after-sales — offering support and maintenance services

End users / buyers — administering Insulin Glulisine Injection

Regulators/standards bodies — setting standards and approvals

The flow of value within the Insulin Glulisine Injection ecosystem is influenced by various control points, such as regulatory approvals and standards, which can impact the adoption of Insulin Glulisine Injection. Dependency risks, including input constraints and supply chain disruptions, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can influence the interactions among ecosystem participants. As the ecosystem differs by region, due to diverse regulatory environments and market conditions, a thorough value chain analysis is necessary to understand the intricacies of the Insulin Glulisine Injection ecosystem.

Recent Industry Insights

The Insulin Glulisine Injection industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between major pharmaceutical companies have led to the creation of new distribution networks, enhancing accessibility to Insulin Glulisine Injection products. Notably, there have been several mergers and acquisitions, particularly in the Asia-Pacific region, which have resulted in increased market consolidation and competitiveness. Furthermore, innovative product launches, such as more convenient and user-friendly injection devices, have catered to the growing demand for self-administered insulin therapies. Regulatory changes, including updated labeling requirements and safety guidelines, have also influenced the Insulin Glulisine Injection market. A shift in consumer trends towards more personalized and technology-driven healthcare solutions has driven the demand for advanced insulin delivery systems.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Insulin Glulisine Injection market. The market attractiveness is moderate, driven by the increasing prevalence of diabetes and the growing demand for fast-acting insulin analogs. The competitive intensity is high, with multiple players operating in the market. The long-term outlook for the Insulin Glulisine Injection market outlook is positive, with opportunities for innovation and growth. However, the demand-supply balance is a key risk factor, as fluctuations in supply can impact market stability. Overall, the innovation landscape is evolving, with a focus on improving patient outcomes and reducing costs.

12 items

1. Executive Summary

2. Insulin Glulisine Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Insulin Glulisine Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Insulin Glulisine Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Insulin Glulisine Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Insulin Glulisine Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Insulin Glulisine Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Insulin Glulisine Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Insulin Glulisine Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Insulin Glulisine Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Insulin Glulisine Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Insulin Glulisine Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Insulin Glulisine Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Insulin Glulisine Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Insulin Glulisine Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Insulin Glulisine Injection Market Competition by Key Manufacturers

9.1. Global Insulin Glulisine Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Insulin Glulisine Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Eli Lilly and Company

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Novo Nordisk

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biocon

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Gan & Lee Pharmaceuticals

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Dongyangguang Pharmaceuticals

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Insulin Glulisine Injection Market

Figure 4: Global Insulin Glulisine Injection Market: Drivers

Figure 5: Global Insulin Glulisine Injection Market: Challenges

Figure 6: Global Insulin Glulisine Injection Market: Trends

Figure 7: Global Insulin Glulisine Injection Market: Opportunity

Figure 8: Global Insulin Glulisine Injection Market: Restraint

Figure 9: Global Insulin Glulisine Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Insulin Glulisine Injection Market Value (USD Million) By Region

Figure 19: Global Insulin Glulisine Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Insulin Glulisine Injection Market Value (USD Million) By Region

Figure 27: Global Insulin Glulisine Injection Market Share (%) By: Regions (2032)

Figure 28: Global Insulin Glulisine Injection Market Volume (K) By Region

Figure 29: Global Insulin Glulisine Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Insulin Glulisine Injection Market Value (USD Million) By Region

Figure 37: Global Insulin Glulisine Injection Market Share (%) By: Regions (2032)

Figure 38: Global Insulin Glulisine Injection Market Volume (K) By Region

Figure 39: Global Insulin Glulisine Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Insulin Glulisine Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Insulin Glulisine Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Insulin Glulisine Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Insulin Glulisine Injection Market Value (USD Million) By Region

Table 14: Global Insulin Glulisine Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Insulin Glulisine Injection Market Volume (K) By Region

Table 31: Global Insulin Glulisine Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Insulin Glulisine Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Insulin Glulisine Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Insulin Glulisine Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Basic Information And Sales Area

Table 52: Sanofi. Products Portfolio

Table 53: Eli Lilly and Company Basic Information And Sales Area

Table 54: Eli Lilly and Company. Products Portfolio

Table 55: Novo Nordisk Basic Information And Sales Area

Table 56: Novo Nordisk. Products Portfolio

Table 57: Biocon Basic Information And Sales Area

Table 58: Biocon. Products Portfolio

Table 59: Gan & Lee Pharmaceuticals Basic Information And Sales Area

Table 60: Gan & Lee Pharmaceuticals. Products Portfolio

Table 61: Dongyangguang Pharmaceuticals Basic Information And Sales Area

Table 62: Dongyangguang Pharmaceuticals. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Insulin Glulisine Injection Market Value (USD Million) By Region

Table 72: Global Insulin Glulisine Injection Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Insulin Glulisine Injection Market Volume (K) By Region

Table 89: Global Insulin Glulisine Injection Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Insulin Glulisine Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.43 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Eli Lilly and Company; Novo Nordisk; Biocon; Gan & Lee Pharmaceuticals; Dongyangguang Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of diabetes and growing awareness about the importance of timely insulin administration are fueling the demand for Insulin Glulisine Injection, thereby driving the market growth.

Advancements in insulin delivery technologies, such as pens and pumps, are making Insulin Glulisine Injection more convenient and accessible, contributing to the market's expansion.

Restraints2 items

Stringent regulatory requirements and high development costs associated with Insulin Glulisine Injection are limiting the entry of new players, thus restraining the market growth.

Competition from alternative diabetes treatments, such as oral medications and glucagon-like peptide-1 receptor agonists, is also hindering the adoption of Insulin Glulisine Injection.

Opportunities2 items

Growing focus on developing biosimilar insulins, including Insulin Glulisine Injection, is expected to reduce costs and increase affordability, further expanding the market.

Challenges2 items

Market Segmentation

Loading chart…

Insulin Glulisine Injection Segmentation Breakdown7 items

Application

Hospital

Clinic

Others

Types

3ml

10ml

Regional Insights

Loading chart…

Competitive Landscape

Sanofi: regional expansion

Eli Lilly and Company: innovation pipeline

Novo Nordisk: premium pricing

Biocon: OEM tie-ups

Gan & Lee Pharmaceuticals: local manufacturing

Dongyangguang Pharmaceuticals: vertical integration

Key Insulin Glulisine Injection Companies6 items

Sanofi

Eli Lilly and Company

Novo Nordisk

Biocon

Gan & Lee Pharmaceuticals

Dongyangguang Pharmaceuticals

Market Ecosystem

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing Insulin Glulisine Injection

Technology providers — developing formulation and delivery technologies

Distributors / channel partners — enabling product distribution

Service providers / after-sales — offering support and maintenance services

End users / buyers — administering Insulin Glulisine Injection

Regulators/standards bodies — setting standards and approvals

Recent Industry Insights

Analyst Overview

Table of Contents